DOCSLIB.ORG

Sandwich Elisas Unique Targets for Innovative Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sandwich Elisas Unique Targets for Innovative Research Sandwich ELISAs Unique targets for innovative research 2400 TARGETS 15 SPECIES 1 MANUFACTURER Over 2,400 kits available Pre-coated 96-well strip plates Validated on serum, plasma and media Manufactured in the U.S.A. Over 2,000 publications Risk-free guarantee SPECIES COVERED: Human, mouse, rat, pig, cow, dog, cat, horse, rhesus macaque, rabbit, chicken, dolphin, zebrafish, sigmodon, and sheep 1.888.494.8555 / RAYBIOTECH.COM RayBiotech R Empowering your proteomics SpeedE LISA Need quantitative detection in less time? The RayBio® SpeedELISA is a sandwich ELISA featuring a compressed workflow that allows full processing in only 3 hours. Over 160 kits currently available including human, mouse, and rat targets. Learn more and browse here: www.raybiotech.com/speedelisa-kits 1 1 2 2 3 ADD ANTIBODIES AND CAPTURE ABS BIND TO PLATE; WASH AND SAMPLES TO MICROPLATE ABANTIGEN COMPLEXES FORM DEVELOP COLOR custom ELISA RayBiotech has a vast library of array-validated antibody pairs you can take advantage of, even if they aren’t currently developed on the 96-well platform. Any antibody pair can be developed into a finished ELISA kit by placing an order for a “custom ELISA.” After a 5-7 week development phase, the final kit will have passed our ELISA quality control tests and be added to our stock kit inventory. The development phase only needs to occur once. If the ELISA fails development, the customer will not be charged anything. Need a custom kit for a target we don’t have a pair to? Need 384-well format? Chemiluminescence-based detection? We can do it! Immunoassay development is RayBiotech’s specialty. Let us tailor an ELISA to your specifications, from antibodies to the final kit. Contact [email protected] for more information and a quote. services Send Us Your Samples, We’ll Send You Results RayBiotech offers full testing services in our GLP-compliant laboratory for all sandwich ELISA kits. Receive reports with data of the highest accuracy and reproducibility. Visit www.raybiotech.com/elisa-testing-service/ for more details. how it works 1 MICROPLATE PRECOATED Why RayBiotech ELISAs? WITH CAPTURE ANTIBODY 2 Made here. By us. For you. RayBiotech is the primary manufacturer of validated ELISA kits, not a reseller. This means not ADD SAMPLE OR STANDARD only can we offer you the best price but also prompt and effective product support. B B Commitment to Quality Our mission is to provide you with reliable assays and reagents, period. Every kit we produce 3 is validated, subjected to a battery of rigorous product-specific quality control tests, and manufactured in compliance with GMP and ISO 13485 standards. ADD BIOTINLABELED DETECTION ANTIBODY Expertise and Experience Creating a consistent and reliable ELISA is no easy task. Immunoassays are the core expertise B B and the focus of our large team of experienced R&D scientists. They meticulously test and optimize antibodies, antigens and buffer systems to develop high-performing ELISAs and corresponding antibody arrays. Their dedicated, collaborative efforts have given us the largest 4 selection of fully validated ELISA kits on the market, with over 2000 unique citations in the scientific literature. ADD HRPCONJUGATED STREPTAVIDIN We Support You If you have questions, concerns or feedback, we’re here to help. Our team of technical support B B specialists are fully qualified and trained on every product line and receive consistently high service ratings. Whether you need to troubleshoot your data or want some advice on how to best design your study, we can provide free consultative services to help you achieve success 5 in your research. Reach out by phone email, or live chat today! ADD COLORIMETRIC We Appreciate You SUBSTRATE RayBiotech’s customer reward program includes valuable discounts and incentives for purchases, publications and product reviews. It’s our way of letting you know we value you and your research efforts. Risk-free Guarantee We understand the risk of trying a new assay with no guarantee of success. That’s why our Specific capture antibodies are coated ELISA kits are covered by a 100% guarantee – so that you can evaluate one of our kits with onto a 96-well plate. Standards and no risks, no worries. If you encounter a problem using one of our ELISA kits and our technical samples are pipetted into the wells; support team cannot satisfactorily resolve it, we will issue you a replacement, credit or refund. the target protein in the standards and samples binds to the immobilized antibody. The wells are washed and the biotin-labeled detection antibody is then added. After washing away the unbound biotinylated antibodies, HRP-conjugated streptavidin is pipetted to the wells, followed by a colorimetric substrate solution. human targets BMP-6 CILP-1 ErbB4 GPV IL-18 R beta Lipocalin-2 # BMP-7 CK-MB Erythropoietin Granzyme A IL-2 Livin 15-PGDH BMP-8 CLEC-2 Erythropoietin R Granzyme B IL-2 R alpha LOX-1 2B4 BMP-9 Clusterin ESAM GRO alpha IL-2 R beta Lp-PLA2 4-1BB BMPR-II c-Myc E-Selectin GRO alpha/beta/gamma IL-20 LRG1 4-1BB Ligand BNP CNTF Growth Hormone IL-21 L-Selectin 6Ckine Brevican CNTF R alpha Growth Hormone R IL-21 R LTA4H Coagulation Factor III F GSTM1 IL-22 Lumican Coagulation Factor VII FABP2 GSTP1 IL-22 R alpha 1 Luteinizing hormone A FABP3 Activin A C Coagulation Factor XI IL-22BP Lymphotactin C1q R1 FABP4 Activin C Coagulation Factor XIV IL-23 LYVE-1 C1qTNF1 FABP5 ADA COCO H IL-23 R C1qTNF5 FABP6 HAI-1 ADAM-12 Complement Factor H IL-24 C1qTNF9 FABP8 HAI-2 ADAM-9 Complement MASP3 IL-26 M C1R FAP HB-EGF MAGP-2 ADAMTS-4 Contactin-1 IL-27 C1S Fas HCC-1 MAPT Adiponectin Corneodesmosin IL-28A C3a Fas Ligand HCC-4 Marapsin Adipsin COX-2 IL-29 C4c Fc gamma RIIB/C hCG beta Matrilin-2 aFGF C-Peptide IL-3 C5a FCRL3 hCG intact Matrilin-3 Aggrecan CRELD2 IL-31 CA125 FCRL5 Hemoglobin Matriptase AgRP CRIM1 IL-32 alpha CA13 Ferritin Hemopexin MBL Albumin CrkL IL-33 CA15-3 Fetuin A Hepassocin MCAM ALCAM CRP IL-34 CA19-9 Fetuin B Hepsin MCP-1 ALDH1A1 CRTAC1 IL-36 alpha CA9 FGF-12 HEXA MCP-2 ALK-6 CRTAM IL-36 gamma Cadherin-11 FGF-16 HGF MCP-3 Alkaline Phosphatase CTACK IL-36 Ra Cadherin-13 FGF-17 HGFR MCP-4 Alpha-2 Macroglobulin CXCL14 IL-37 Calcitonin FGF-19 HIF-1 alpha M-CSF Alpha-fetoprotein CXCL16 IL-4 Calreticulin FGF-20 HPRG MD-2 AMICA CXCL17 I-309 Carboxylesterase 1 FGF-21 HSP27 MDC AmiGO2 Cyclophilin A ICAM-1 Carboxylesterase 2 FGF-23 HSP60 Mer Aminopeptidase LRAP Cyr61 ICAM-3 Carboxypeptidase A1 FGF-4 HSP70 Mesothelin Aminopeptidase N Cystatin C ICOS Carboxypeptidase B1 FGF-5 HTRA2 METAP2 Aminopeptidase P1 Cystatin D IL-5 Carboxypeptidase B2 FGF-6 HVEM MFG-E8 Amnionless Cystatin SN IL-5 R alpha Cardiac Troponin I FGF-7 MICA Amphiregulin Cytokeratin 18 IL-6 Cardiotrophin-1 FGF-9 MICB Amyloid beta 1-40 Cytokeratin 19 IL-6 R Carnosine Dipeptidase-1 Fibronectin I Midkine Angiogenin Cytokeratin 8 IL-7 Caspase-3 Ficolin-2 IDO MIF Angiopoietin-1 IL-7 R alpha Caspase-7 FKBP51 IDUA MIG Angiopoietin-2 IL-8 Cathepsin C FLRG IFN-alpha MIP-1 alpha Angiopoietin-4 D IL-9 Cathepsin D DAN FLRT2 IFN-alpha/beta R2 MIP-1 beta Angiostatin Importin alpha 2 Cathepsin L DCBLD2 Flt-3 IFN-gamma MIP-1 delta Angiotensinogen Inhibin A Cathepsin S DcR3 Flt-3 Ligand IFN-gamma R1 MIP-3 alpha ANGPTL3 Insulin CCL28 DC-SIGNR Follistatin IGF-1 MIP-3 beta ANGPTL4 Integrin alpha-2 CD14 D-Dimer FOLR1 IGF-1 R MMP-1 ANGPTL7 Integrin alpha-M CD155 Decorin FOLR3 IGF-2 R MMP-10 Annexin A1 IP-10 CD163 Dectin-1 Fractalkine IGFBP-1 MMP-12 ApoA1 Islet-1 CD177 Desmin FSH IGFBP-2 MMP-13 ApoA2 I-TAC CD200 Desmocollin-3 Furin IGFBP-3 MMP-2 ApoB CD229 Desmoglein-1 IGFBP-4 MMP-3 ApoB100 CD23 Desmoglein-2 IGFBP-5 MMP-7 ApoC1 J CD26 DKK-1 G IGFBP-6 Jagged 1 MMP-8 ApoC2 CD27 Ligand DKK-3 Galectin-1 IGFBP-rp1 JAM-A MMP-9 ApoC3 CD30 DKK-4 Galectin-3 IgG JAM-B MMR ApoE CD30 Ligand DLEC Galectin-7 IgG1 JAM-C MPIF-1 ApoE2 CD34 DLL1 Galectin-8 IL-1 alpha MSP alpha/beta ApoE3 CD35 DMP-1 Galectin-9 IL-1 beta Myoglobin ApoE4 CD36 DNAM-1 GAPHD IL-1 R1 K ApoH CD38 DPPII Gas 1 IL-1 R2 Kallikrein 10 Arginase 1 CD4 Draxin Gas 6 IL-1 R4 Kallikrein 14 N Artemin CD40 DSCAM-L1 GASP-1 IL-1 R6 Kallikrein 6 NAP-2 AXL CD40 Ligand Dtk GATA-1 IL-1 Ra Kininogen NCAM-1 CD42b GCP-2 IL-10 KIRREL3 Nectin-2 CD51 GCSF IL-10 R alpha Kynureninase NELL1 B GCSF R IL-10 R beta Neprilysin B7-H1 CD59 E ECM-1 GDF-11 IL-11 Nesfatin-1 B7-H2 CD69 EDA-A2 GDF-15 IL-12 p40 L Nestin BACE-1 CD74 EGF GDF-8 IL-12 p70 L1CAM Neurocan BCAM CD80 EGFR GDNF IL-13 Lactoferrin Neuropilin-2 bcl-w CD86 EGR1 GFR alpha-3 IL-13 R alpha 1 LAG-3 NG2 BCMA CD99 EG-VEGF Ghrelin IL-13 R alpha 2 LAIR1 NGFR BDNF CDNF ENA-78 GITR IL-15 Laminin alpha 4 Nidogen-1 beta IG-H3 CEA Endoglin GITR Ligand IL-15 R alpha LAMP1 Nidogen-2 Beta-2 Microglobulin CEACAM-1 Endostatin GLI-3 IL-16 LAMP2 NMNAT-1 Betacellulin Cerberus 1 Endothelin-1 GLP-1 IL-17 RA LBP Nogo-A beta-NGF CFHR1 eNOS Glucagon IL-17 RC LDL R Norrin bFGF CFHR5 EN-RAGE Glypican 1 IL-17A Lefty-A Notch-1 Biglycan Chemerin Eotaxin-1 Glypican 3 IL-17B Legumain Notch-3 BLC CHI3L1 Eotaxin-2 GM-CSF IL-17E Leptin NOV BMP-15 Chitotriosidase Eotaxin-3 GM-CSF R alpha IL-17F LIF NPTXR BMP-2 Chordin-Like-1 EphA2 GOLM1 IL-18 LIGHT Nr-CAM BMP-4 CHST4 ErbB2 gp130 IL-18 BP alpha LILRB4 NRF2 BMP-5 cIAP-1 cIAP-2 ErbB3 GPR56 IL-18 R alpha LIMPII NRG1-alpha NRG1-beta 1 PECAM-1 RANTES SERPIN G1 TECK TRAIL R4 VEGF-B NT-3 Pentraxin-3 RBP4 sFRP-1 Tenascin C Transferrin VEGF-C NT-4 Pepsinogen 1 Reg1B sFRP-3 Tenascin R Transglutaminase 2 VEGF-D NTB-A Pepsinogen 2 Renin SHBG TFF3 Transglutaminase 3 VEGFR1 Periostin Resistin ShhN TFPI Trappin-2 VEGFR2 PGRP-S Ret SIGIRR
Load more

Recommended publications
  • Prognostic Value of CXCL17 and CXCR8 Expression in Patients with Colon Cancer
    ONCOLOGY LETTERS 20: 2711-2720, 2020 Prognostic value of CXCL17 and CXCR8 expression in patients with colon cancer HONGYAN YAO1,2, YUFENG LV3, XUEFENG BAI4, ZHAOJIN YU4 and XIAOJIAN LIU1 1Department of Pharmacology, School of Basic Medical Sciences, Jinzhou Medical University; 2Nuclear Medicine Department, Jinzhou Central Hospital, Jinzhou, Liaoning 121001; 3Department of Respiration and Critical Care, The Affiliated Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011; 4Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning 110001, P.R. China Received October 11, 2019; Accepted May 27, 2020 DOI: 10.3892/ol.2020.11819 Abstract. C-X-C motif chemokine ligand 17 (CXCL17) is a CXCL17/CXCR8 signalling may be involved in colon cancer mucous chemokine and its expression is highly correlated with and contribute to improved patient outcomes. that of G protein-coupled receptor 35 (GPR35), which has been confirmed as its receptor and named C‑X‑C motif chemokine Introduction receptor 8 (CXCR8). CXCL17 is upregulated in several types of cancer. However, the biological role of this chemokine Chemokines are a large family of cytokines serving important in colon cancer remains unknown. In the present study, the roles in the immune system, such as the regulation of cell traf- expression levels of CXCL17 and CXCR8 were examined ficking to inflammatory sites (1). By regulating the activity of using immunohistochemistry in 101 colon cancer tissues and cells in homeostasis and signal transduction, chemokines are 79 healthy tumour-adjacent tissues. CXCL17 and CXCR8 involved in numerous physiological and pathological processes expression levels were increased in the colon cancer samples such as angiogenesis, embryonic development, wound healing, compared with tumour-adjacent samples.
    [Show full text]
  • Fog2 Is Critical for Cardiac Function and Maintenance of Coronary Vasculature in the Adult Mouse Heart
    Fog2 is critical for cardiac function and maintenance of coronary vasculature in the adult mouse heart Bin Zhou, … , Sergei G. Tevosian, William T. Pu J Clin Invest. 2009;119(6):1462-1476. https://doi.org/10.1172/JCI38723. Research Article Cardiology Aberrant transcriptional regulation contributes to the pathogenesis of both congenital and adult forms of heart disease. While the transcriptional regulator friend of Gata 2 (FOG2) is known to be essential for heart morphogenesis and coronary development, its tissue-specific function has not been previously investigated. Additionally, little is known about the role of FOG2 in the adult heart. Here we used spatiotemporally regulated inactivation of Fog2 to delineate its function in both the embryonic and adult mouse heart. Early cardiomyocyte-restricted loss of Fog2 recapitulated the cardiac and coronary defects of the Fog2 germline murine knockouts. Later cardiomyocyte-restricted loss ofF og2 (Fog2MC) did not result in defects in cardiac structure or coronary vessel formation. However, Fog2MC adult mice had severely depressed ventricular function and died at 8–14 weeks. Fog2MC adult hearts displayed a paucity of coronary vessels, associated with myocardial hypoxia, increased cardiomyocyte apoptosis, and cardiac fibrosis. Induced inactivation of Fog2 in the adult mouse heart resulted in similar phenotypes, as did ablation of the FOG2 interaction with the transcription factor GATA4. Loss of the FOG2 or FOG2-GATA4 interaction altered the expression of a panel of angiogenesis-related genes. Collectively, our data indicate that FOG2 regulates adult heart function and coronary angiogenesis. Find the latest version: https://jci.me/38723/pdf Research article Fog2 is critical for cardiac function and maintenance of coronary vasculature in the adult mouse heart Bin Zhou,1,2 Qing Ma,1 Sek Won Kong,1 Yongwu Hu,1,3 Patrick H.
    [Show full text]
  • Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas
    Supplementary Online Content Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013.4773 eTable. List of All of the Proteins Identified by Proteomics This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable. List of All of the Proteins Identified by Proteomics Protein Name Prop 12 mo/4 Pred 12 mo/4 Δ Prop to Pred mo mo Myeloperoxidase OS=Homo sapiens GN=MPO 26.00 143.00 ‐117.00 Lactotransferrin OS=Homo sapiens GN=LTF 114.00 205.50 ‐91.50 Matrix metalloproteinase‐9 OS=Homo sapiens GN=MMP9 5.00 36.00 ‐31.00 Neutrophil elastase OS=Homo sapiens GN=ELANE 24.00 48.00 ‐24.00 Bleomycin hydrolase OS=Homo sapiens GN=BLMH 3.00 25.00 ‐22.00 CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 4.00 26.00 ‐22.00 S10A8_HUMAN Protein S100‐A8 OS=Homo sapiens GN=S100A8 PE=1 14.67 30.50 ‐15.83 SV=1 IL1F9_HUMAN Interleukin‐1 family member 9 OS=Homo sapiens 1.00 15.00 ‐14.00 GN=IL1F9 PE=1 SV=1 MUC5B_HUMAN Mucin‐5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 2.00 14.00 ‐12.00 MUC4_HUMAN Mucin‐4 OS=Homo sapiens GN=MUC4 PE=1 SV=3 1.00 12.00 ‐11.00 HRG_HUMAN Histidine‐rich glycoprotein OS=Homo sapiens GN=HRG 1.00 12.00 ‐11.00 PE=1 SV=1 TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 17.00 28.00 ‐11.00 CATG_HUMAN Cathepsin G OS=Homo
    [Show full text]
  • Cytokine Nomenclature
    RayBiotech, Inc. The protein array pioneer company Cytokine Nomenclature Cytokine Name Official Full Name Genbank Related Names Symbol 4-1BB TNFRSF Tumor necrosis factor NP_001552 CD137, ILA, 4-1BB ligand receptor 9 receptor superfamily .2. member 9 6Ckine CCL21 6-Cysteine Chemokine NM_002989 Small-inducible cytokine A21, Beta chemokine exodus-2, Secondary lymphoid-tissue chemokine, SLC, SCYA21 ACE ACE Angiotensin-converting NP_000780 CD143, DCP, DCP1 enzyme .1. NP_690043 .1. ACE-2 ACE2 Angiotensin-converting NP_068576 ACE-related carboxypeptidase, enzyme 2 .1 Angiotensin-converting enzyme homolog ACTH ACTH Adrenocorticotropic NP_000930 POMC, Pro-opiomelanocortin, hormone .1. Corticotropin-lipotropin, NPP, NP_001030 Melanotropin gamma, Gamma- 333.1 MSH, Potential peptide, Corticotropin, Melanotropin alpha, Alpha-MSH, Corticotropin-like intermediary peptide, CLIP, Lipotropin beta, Beta-LPH, Lipotropin gamma, Gamma-LPH, Melanotropin beta, Beta-MSH, Beta-endorphin, Met-enkephalin ACTHR ACTHR Adrenocorticotropic NP_000520 Melanocortin receptor 2, MC2-R hormone receptor .1 Activin A INHBA Activin A NM_002192 Activin beta-A chain, Erythroid differentiation protein, EDF, INHBA Activin B INHBB Activin B NM_002193 Inhibin beta B chain, Activin beta-B chain Activin C INHBC Activin C NM005538 Inhibin, beta C Activin RIA ACVR1 Activin receptor type-1 NM_001105 Activin receptor type I, ACTR-I, Serine/threonine-protein kinase receptor R1, SKR1, Activin receptor-like kinase 2, ALK-2, TGF-B superfamily receptor type I, TSR-I, ACVRLK2 Activin RIB ACVR1B
    [Show full text]
  • Cxcl17 and Its Association with T Cells
    Hernández-Ruiz et al., Arch Autoimmune Archives of Autoimmune Diseases Dis 2020; 1(1):28-31. Commentary Cxcl17 and its association with T cells Marcela Hernández-Ruiz1, Albert Zlotnik2* 1Lymphotrek, San Diego, CA, United Keywords: CXCL17, Auto immunities, T cells, IL-23 States Abbreviations: BALF: Bronchoalveolar Lavage Fluid; CLP: Common Lymphoid Progenitor; CNS: 2Department of Physiology Central Nervous System; DP: Double Positive; EAE: Experimental Autoimmune Encephalomyelitis; LN: and Biophysics and Institute for Lymph Nodes; LTHSC: Long-term Hematopoietic Stem Cells; MHC: Major Histocompatibility Complex; Immunology, University of California Irvine, Irvine, CA, United States MOG: Myelin Oligodendrocyte Glycoprotein; STHCS: Short-Term Hematopoietic Stem Cells; TCR: T cell Receptor *Author for correspondence: Email: [email protected] We recently published an article describing the importance of CXCL17 in T cell responses [1]. In summary, we observed the following: Received date: September 02, 2020 Accepted date: September 23, 2020 1) Cxcl17 is necessary to maintain normal ratios of T cell subpopulations in lymph nodes (LN). 2) Cxcl17-/- mice develop more intense inflammatory responses than wild type mice. Copyright: © 2020 Hernández-Ruiz Cxcl17 is a mucosal chemokine predominantly expressed in mucosal tissues of the respiratory M, et al. This is an open-access article tract and digestive system [2-4]. However, it is also expressed in primary immune tissues such as distributed under the terms of the bone marrow and thymus (where its function is currently unknown- Table 1). Microarray data Creative Commons Attribution License, from the Immgen database of 298 purified immune cell subpopulations, and consistent with the which permits unrestricted use, distribution, and reproduction in any analysis shown in table 1, indicates that Cxcl17 is expressed in the thymus.
    [Show full text]
  • The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors—A Review of Literature
    International Journal of Molecular Sciences Review The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors—A Review of Literature Jan Korbecki 1 , Klaudyna Kojder 2, Patrycja Kapczuk 1, Patrycja Kupnicka 1 , Barbara Gawro ´nska-Szklarz 3 , Izabela Gutowska 4 , Dariusz Chlubek 1 and Irena Baranowska-Bosiacka 1,* 1 Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta´nców Wielkopolskich 72 Av., 70-111 Szczecin, Poland; [email protected] (J.K.); [email protected] (P.K.); [email protected] (P.K.); [email protected] (D.C.) 2 Department of Anaesthesiology and Intensive Care, Pomeranian Medical University in Szczecin, Unii Lubelskiej 1, 71-281 Szczecin, Poland; [email protected] 3 Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University in Szczecin, Powsta´nców Wielkopolskich 72 Av., 70-111 Szczecin, Poland; [email protected] 4 Department of Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta´nców Wlkp. 72 Av., 70-111 Szczecin, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-914661515 Abstract: Hypoxia is an integral component of the tumor microenvironment. Either as chronic or cycling hypoxia, it exerts a similar effect on cancer processes by activating hypoxia-inducible factor-1 (HIF-1) and nuclear factor (NF-κB), with cycling hypoxia showing a stronger proinflammatory influ- ence. One of the systems affected by hypoxia is the CXC chemokine system. This paper reviews all available information on hypoxia-induced changes in the expression of all CXC chemokines (CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8 (IL-8), CXCL9, CXCL10, CXCL11, CXCL12 Citation: Korbecki, J.; Kojder, K.; Kapczuk, P.; Kupnicka, P.; (SDF-1), CXCL13, CXCL14, CXCL15, CXCL16, CXCL17) as well as CXC chemokine receptors— Gawro´nska-Szklarz,B.; Gutowska, I.; CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CXCR7 and CXCR8.
    [Show full text]
  • The Chemokine System in Innate Immunity
    Downloaded from http://cshperspectives.cshlp.org/ on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press The Chemokine System in Innate Immunity Caroline L. Sokol and Andrew D. Luster Center for Immunology & Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114 Correspondence: [email protected] Chemokines are chemotactic cytokines that control the migration and positioning of immune cells in tissues and are critical for the function of the innate immune system. Chemokines control the release of innate immune cells from the bone marrow during homeostasis as well as in response to infection and inflammation. Theyalso recruit innate immune effectors out of the circulation and into the tissue where, in collaboration with other chemoattractants, they guide these cells to the very sites of tissue injury. Chemokine function is also critical for the positioning of innate immune sentinels in peripheral tissue and then, following innate immune activation, guiding these activated cells to the draining lymph node to initiate and imprint an adaptive immune response. In this review, we will highlight recent advances in understanding how chemokine function regulates the movement and positioning of innate immune cells at homeostasis and in response to acute inflammation, and then we will review how chemokine-mediated innate immune cell trafficking plays an essential role in linking the innate and adaptive immune responses. hemokines are chemotactic cytokines that with emphasis placed on its role in the innate Ccontrol cell migration and cell positioning immune system. throughout development, homeostasis, and in- flammation. The immune system, which is de- pendent on the coordinated migration of cells, CHEMOKINES AND CHEMOKINE RECEPTORS is particularly dependent on chemokines for its function.
    [Show full text]
  • The Tumor Suppressor Notch Inhibits Head and Neck Squamous Cell
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2015 THE TUMOR SUPPRESSOR NOTCH INHIBITS HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) TUMOR GROWTH AND PROGRESSION BY MODULATING PROTO-ONCOGENES AXL AND CTNNAL1 (α-CATULIN) Shhyam Moorthy Shhyam Moorthy Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Biochemistry, Biophysics, and Structural Biology Commons, Cancer Biology Commons, Cell Biology Commons, and the Medicine and Health Sciences Commons Recommended Citation Moorthy, Shhyam and Moorthy, Shhyam, "THE TUMOR SUPPRESSOR NOTCH INHIBITS HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) TUMOR GROWTH AND PROGRESSION BY MODULATING PROTO-ONCOGENES AXL AND CTNNAL1 (α-CATULIN)" (2015). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 638. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/638 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. THE TUMOR SUPPRESSOR NOTCH INHIBITS HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) TUMOR GROWTH AND PROGRESSION BY MODULATING PROTO-ONCOGENES AXL AND CTNNAL1 (α-CATULIN) by Shhyam Moorthy, B.S.
    [Show full text]
  • GP130 Cytokines in Breast Cancer and Bone
    cancers Review GP130 Cytokines in Breast Cancer and Bone Tolu Omokehinde 1,2 and Rachelle W. Johnson 1,2,3,* 1 Program in Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA; [email protected] 2 Vanderbilt Center for Bone Biology, Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA 3 Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA * Correspondence: [email protected]; Tel.: +1-615-875-8965 Received: 14 December 2019; Accepted: 29 January 2020; Published: 31 January 2020 Abstract: Breast cancer cells have a high predilection for skeletal homing, where they may either induce osteolytic bone destruction or enter a latency period in which they remain quiescent. Breast cancer cells produce and encounter autocrine and paracrine cytokine signals in the bone microenvironment, which can influence their behavior in multiple ways. For example, these signals can promote the survival and dormancy of bone-disseminated cancer cells or stimulate proliferation. The interleukin-6 (IL-6) cytokine family, defined by its use of the glycoprotein 130 (gp130) co-receptor, includes interleukin-11 (IL-11), leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), and cardiotrophin-1 (CT-1), among others. These cytokines are known to have overlapping pleiotropic functions in different cell types and are important for cross-talk between bone-resident cells. IL-6 cytokines have also been implicated in the progression and metastasis of breast, prostate, lung, and cervical cancer, highlighting the importance of these cytokines in the tumor–bone microenvironment. This review will describe the role of these cytokines in skeletal remodeling and cancer progression both within and outside of the bone microenvironment.
    [Show full text]
  • Disease-Related Cellular Protein Networks Differentially Affected
    www.nature.com/scientificreports OPEN Disease‑related cellular protein networks diferentially afected under diferent EGFR mutations in lung adenocarcinoma Toshihide Nishimura1,8*, Haruhiko Nakamura1,2,8, Ayako Yachie3,8, Takeshi Hase3,8, Kiyonaga Fujii1,8, Hirotaka Koizumi4, Saeko Naruki4, Masayuki Takagi4, Yukiko Matsuoka3, Naoki Furuya5, Harubumi Kato6,7 & Hisashi Saji2 It is unclear how epidermal growth factor receptor EGFR major driver mutations (L858R or Ex19del) afect downstream molecular networks and pathways. This study aimed to provide information on the infuences of these mutations. The study assessed 36 protein expression profles of lung adenocarcinoma (Ex19del, nine; L858R, nine; no Ex19del/L858R, 18). Weighted gene co-expression network analysis together with analysis of variance-based screening identifed 13 co-expressed modules and their eigen proteins. Pathway enrichment analysis for the Ex19del mutation demonstrated involvement of SUMOylation, epithelial and mesenchymal transition, ERK/mitogen- activated protein kinase signalling via phosphorylation and Hippo signalling. Additionally, analysis for the L858R mutation identifed various pathways related to cancer cell survival and death. With regard to the Ex19del mutation, ROCK, RPS6KA1, ARF1, IL2RA and several ErbB pathways were upregulated, whereas AURK and GSKIP were downregulated. With regard to the L858R mutation, RB1, TSC22D3 and DOCK1 were downregulated, whereas various networks, including VEGFA, were moderately upregulated. In all mutation types, CD80/CD86 (B7), MHC, CIITA and IFGN were activated, whereas CD37 and SAFB were inhibited. Costimulatory immune-checkpoint pathways by B7/CD28 were mainly activated, whereas those by PD-1/PD-L1 were inhibited. Our fndings may help identify potential therapeutic targets and develop therapeutic strategies to improve patient outcomes.
    [Show full text]
  • Exploration of Prognostic Biomarkers and Therapeutic Targets in the Microenvironment of Bladder Cancer Based on CXC Chemokines
    Exploration of Prognostic Biomarkers and Therapeutic Targets in The Microenvironment of Bladder Cancer Based on CXC Chemokines Xiaoqi Sun Department of Urology, Kaiping Central Hospital, Kaiping, 529300, China Qunxi Chen Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China Lihong Zhang Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China Jiewei Chen Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China Xinke Zhang ( [email protected] ) Sun Yat-sen University Cancer Center Research Keywords: Bladder cancer, Biomarkers, CXC Chemokines, Microenvironment Posted Date: February 24th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-223127/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/29 Abstract Background: Bladder cancer (BLCA) has a high rate of morbidity and mortality, and is considered as one of the most malignant tumors of the urinary system. Tumor cells interact with surrounding interstitial cells, playing a key role in carcinogenesis and progression, which is partly mediated by chemokines. CXC chemokines exert anti‐tumor biological roles in the tumor microenvironment and affect patient prognosis. Nevertheless, their expression and prognostic values patients with BLCA remain unclear. Methods: We used online tools, including Oncomine, UALCAN, GEPIA, GEO databases, cBioPortal, GeneMANIA, DAVID 6.8, Metascape, TRUST (version 2.0), LinkedOmics, TCGA, and TIMER2.0 to perform the relevant analysis. Results: The mRNA levels of C-X-C motif chemokine ligand (CXCL)1, CXCL5, CXCL6, CXCL7, CXCL9, CXCL10, CXCL11, CXCL13, CXCL16, and CXCL17 were increased signicantly increased, and those of CXCL2, CXCL3, and CXCL12 were decreased signicantly in BLCA tissues as assessed using the Oncomine, TCGA, and GEO databases.
    [Show full text]
  • Article Characterization of HMGB1/2 Interactome in Prostate Cancer by Yeast Two Hybrid Approach: Potential Pathobiological Implications
    Article Characterization of HMGB1/2 Interactome in Prostate Cancer by Yeast Two Hybrid Approach: Potential Pathobiological Implications Aida Barreiro-Alonso 1,†, María Cámara-Quílez 1,†, Martín Salamini-Montemurri 1, Mónica Lamas- Maceiras 1, Ángel Vizoso-Vázquez 1, Esther Rodríguez-Belmonte 1, María Quindós-Varela 2, Olaia Martínez-Iglesias 3, Angélica Figueroa 3 and María-Esperanza Cerdán 1,* Table S1. Association of proteins that interact with Hmgb1 or Hmgb2 to cancer hallmarks. Cancer Hallmark Protein Model Reference MAP1B Colorectal cancers [109] GENOMIC INSTABILITY AND Liver adenocarcinoma (SKHep1) and NOP53 [110] MUTATIONS/ CHANGES IN glioblastoma (T98G) cell lines TELOMERASE ACTIVITY RSF1 Ovarian cells [111] SRSF3 Ovarian cancer [112] C1QBP Breast cancer [54,113] cFOS Bladder cancer [114] cFOS Breast cancer [115] DLAT Gastric Cancer [116] Human melanoma (A7), Prostate cancer FLNA [117] (PC3) cell lines GOLM1 Hepatocellular carcinoma [118] GOLM1 Breast cancer [119] GOLM1 Lung proliferation [120] GOLM1 Prostate cancer [82] SUSTAINING PROLIFERATIVE Hox-A10 Prostate cancer cell line PC-3 [58] SIGNALLING/ CELL Hox-A10 Ovarian cancer cell lines [121,122] PROLIFERATION NOP53 Breast cancer [123] PSMA7 Cervical cancer [124] PTPN2 Epithelial carcinogenesis [125] RASAL2 hepatocellular carcinoma [126] RSF1 Prostate cancer [95] RSF1 Nasopharyngeal carcinoma [127] SPIN1 Glioma [128] TGM3 Esophageal cancer [129] UBE2E3 Retinal pigment epithelial (RPE) [130] Vigilin Hepatocellular carcinomas [131] WNK4 Kidney [100] C1QBP Prostate cancer [48]
    [Show full text]